OIG: Medicaid could save $1.4 billion by requiring rebates from generic drug makers

Share this content:
Generic drug prices outpaced inflation in 22% of the medications studied.
Generic drug prices outpaced inflation in 22% of the medications studied.

Requiring generic drug makers to pay rebates when they raised prices faster than inflation would have trimmed $1.4 billion from Medicaid outlays over the past decade, notes a report from the Office of Inspector General.

Auditors found that generic drug prices outpaced inflation in 22% of the medications they examined for the study. Branded medications are already required to issue rebates when this happens.

The OIG encouraged the Centers for Medicare & Medicaid Services to consider seeking legislative authority that would extend the same rule to companies making generic drugs.


close

Next Article in News

In Focus

July 18

A truckload of charity

Gainesville, FL 

The Village at Gainesville recently donated a truckload of used appliances from its residences to the Bread of the Mighty Food Bank.

Subscribe for free!

Never Miss out

Get top stories sent to your inbox